AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3510774 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (25 micrograms/kg)
Number of subjects: 15
Study 3510774 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (5 micrograms/kg/min)
Number of subjects: 15
Study 31676522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensation Awareness Focused Training (SÄ€F‐T), 1 session daily for 3 days
Number of subjects: 10
Study 31676522 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 10
Study 28251224 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium (50 mg)
Number of subjects: 120
Study 28251224 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (1 gram)
Number of subjects: 120
Study 28251224 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (400 mg)
Number of subjects: 120
Study 28251224 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative analgesics (general)
Number of subjects: 120
Study 26931619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroids for 1 week
Number of subjects: 380
Study 26931619 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo for 1 week
Number of subjects: 380
Study 25109754 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery grafts in diabetic patients
Number of subjects: 529
Study 25109754 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein grafts in diabetic patients
Number of subjects: 529
Study 25109754 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery grafts in nondiabetic patients
Number of subjects: 529
Study 25109754 — intervention group
Group type: EXPERIMENTAL
Intervention: Major adverse cardiac events in diabetic patients
Number of subjects: 529
Study 25109754 — intervention group
Group type: COMPARATOR
Intervention: Major adverse cardiac events in nondiabetic patients
Number of subjects: 529
Study 23091142 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis ANSB060 (E60)
Number of subjects: 0
Study 23091142 — intervention group
Group type: COMPARATOR
Intervention: Control group (C20, C40, C60)
Number of subjects: 0
Study 23091142 — intervention group
Group type: COMPARATOR
Intervention: Control group (C40 and C60)
Number of subjects: 0
Study 23091142 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis ANSB060
Number of subjects: 0
Study 19667110 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1507
Study 19667110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1507
Study 17697277 — intervention group
Group type: EXPERIMENTAL
Intervention: Levo-alpha-acetylmethadol (LAAM)
Number of subjects: 315
Study 17697277 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance (MM)
Number of subjects: 315
Study 14678340 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg oral dose
Number of subjects: 234
Study 14678340 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg day(-1), 30 mg day(-1), or 40 mg day(-1)
Number of subjects: 234
Study 14678340 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg day(-1), 40 mg day(-1), or 80 mg day(-1)
Number of subjects: 234
Study 14678340 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (various doses)
Number of subjects: 234
Study 11822006 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole as an adjunct to endoscopic intervention
Number of subjects: 0
Study 11822006 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction guide
Number of subjects: 0
Study 11822006 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound examination of the ulcer base
Number of subjects: 0
Study 11822006 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical methods of hemostasis
Number of subjects: 0
Study 10444645 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise (50% peak O(2) uptake)
Number of subjects: 11
Study 10444645 — intervention group
Group type: COMPARATOR
Intervention: Seated rest (Control session)
Number of subjects: 11
Study 8577182 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐methamphetamine (30 mg/70 kg) administered at 0930 h
Number of subjects: 10
Study 8577182 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐methamphetamine (30 mg/70 kg) administered at 2130 h
Number of subjects: 10
Study 8577182 — intervention group
Group type: COMPARATOR
Intervention: D‐methamphetamine (30 mg/70 kg)
Number of subjects: 10
Study 2197892 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostenone
Number of subjects: 66
Study 2197892 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 66
Study 39574 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg MJ-9184-1
Number of subjects: 10
Study 39574 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg MJ-9184-1
Number of subjects: 10
Study 39574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31436925 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish applied four times a year, every three months for two years
Number of subjects: 504
Study 31436925 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride varnish)
Number of subjects: 504
Study 31436925 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 504
Study 27863058 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (diet and physical activity)
Number of subjects: 90
Study 27863058 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90
Study 25293728 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncoplanar VMAT (NC-VMAT)
Number of subjects: 10
Study 25293728 — intervention group
Group type: EXPERIMENTAL
Intervention: Coplanar VMAT (co-VMAT)
Number of subjects: 10
Study 25293728 — intervention group
Group type: COMPARATOR
Intervention: Noncoplanar IMRT (NC-IMRT)
Number of subjects: 10
Study 23433279 — intervention group
Group type: EXPERIMENTAL
Intervention: CIT + EP
Number of subjects: 24
Study 23433279 — intervention group
Group type: EXPERIMENTAL
Intervention: CIT
Number of subjects: 24
Study 23433279 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 24
Study 20598897 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis and full coverage stabilizing splint
Number of subjects: 20
Study 20598897 — intervention group
Group type: COMPARATOR
Intervention: Arthrocentesis only
Number of subjects: 20
Study 19956161 — intervention group
Group type: EXPERIMENTAL
Intervention: Scripted 10-min interaction with a radiographer plus a booklet
Number of subjects: 867
Study 19956161 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet alone
Number of subjects: 867
Study 19956161 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 867
Study 16754583 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Screening
Number of subjects: 3464
Study 16754583 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Screening and Discussion
Number of subjects: 3464
Study 16754583 — intervention group
Group type: COMPARATOR
Intervention: Invited group
Number of subjects: 3464
Study 16754583 — intervention group
Group type: COMPARATOR
Intervention: Internal control group
Number of subjects: 3464
Study 15032285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol (IVA) - 20 mg bolus intravenously, PCA programmed to deliver 20 mg bolus with 10 mg/hour infusion rate
Number of subjects: 40
Study 15032285 — intervention group
Group type: COMPARATOR
Intervention: Epidural tramadol (EA) - administered epidurally 5 minutes before induction, PCA programmed to deliver 20 mg bolus with 10 mg/hour infusion rate
Number of subjects: 40
Study 11696805 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg desmopressin intranasally
Number of subjects: 40
Study 11696805 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (placebo)
Number of subjects: 40
Study 9137792 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI + melphalan 140 mg/m2
Number of subjects: 100
Study 9137792 — intervention group
Group type: COMPARATOR
Intervention: melphalan 200 mg/m2
Number of subjects: 100
Study 9137792 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose treatment (both groups)
Number of subjects: 100
Study 7970538 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (IAL)
Number of subjects: 60
Study 7970538 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (Healon)
Number of subjects: 60
Study 7970538 — intervention group
Group type: COMPARATOR
Intervention: Hydroxypropyl methylcellulose (Oculose)
Number of subjects: 60
Study 6383734 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 370 cream (1% clotrimazole/0.05% betamethasone dipropionate)
Number of subjects: 331
Study 6383734 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate
Number of subjects: 331
Study 6383734 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole
Number of subjects: 331
Study 6383734 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 370 cream
Number of subjects: 331
Study 30580246 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 24
Study 30580246 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study 30480393 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal vibratory stimulation at 80 Hz
Number of subjects: 27
Study 30480393 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal vibratory stimulation at 300 Hz
Number of subjects: 27
Study 30480393 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 27
Study 26568562 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile of patients with greater brain volume loss (BVL) at 24 months
Number of subjects: 0
Study 26568562 — intervention group
Group type: COMPARATOR
Intervention: Quartile of patients with least amount of brain volume loss (BVL) at 24 months
Number of subjects: 0
Study 25095313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano hydroxyapatite (Nano‐HA)
Number of subjects: 30
Study 25095313 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 30
Study 25095313 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide (Dycal)
Number of subjects: 30
Study 23534323 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum treatment (3 times/day for 3 months)
Number of subjects: 60
Study 23534323 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish
Number of subjects: 60
Study 21129077 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle program provided by nurse practitioners (NPs)
Number of subjects: 58
Study 21129077 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care
Number of subjects: 58
Study 18246895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice bag secured to the lateral ankle joint for 20 minutes)
Number of subjects: 27
Study 18246895 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 27
Study 16679671 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 250
Study 16679671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 15679251 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative surgical resection
Number of subjects: 0
Study 15679251 — intervention group
Group type: EXPERIMENTAL
Intervention: More radical resection
Number of subjects: 0
Study 15679251 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment strategies
Number of subjects: 0
Study 15679251 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant or adjuvant treatments
Number of subjects: 0
Study 11005744 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy training for apraxia
Number of subjects: 33
Study 8874339 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (30 mg/m2/week)
Number of subjects: 216
Study 8874339 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV (425 mg/m2 and 20 mg/m2 for 5 consecutive days every 4 weeks)
Number of subjects: 216
Study 1900012 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 352
Study 1900012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 6383740 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 8 mg four times daily (qid)
Number of subjects: 44
Study 6383740 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 64 mg every other day (qod)
Number of subjects: 44
Study 6383740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 31129354 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-matched unrelated donor (MUD) hematopoietic stem cell transplantation (HSCT)
Number of subjects: 0
Study 31129354 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive therapy (IST) with eltrombopag
Number of subjects: 0
Study 27477840 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanolin (n = 93)
Number of subjects: 186
Study 27477840 — intervention group
Group type: COMPARATOR
Intervention: Usual postpartum care (n = 93)
Number of subjects: 186
Study 25880227 — intervention group
Group type: EXPERIMENTAL
Intervention: GAME intervention (goal-oriented activity-based, environmental enrichment therapy programme)
Number of subjects: 13
Study 25880227 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 13
Study 23708871 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU/day for 1 week before to 4 weeks after I therapy)
Number of subjects: 36
Study 23708871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 36
Study 21136299 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.2 mg/kg body weight)
Number of subjects: 180
Study 21136299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 21136299 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 180
Study 21136299 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine and Placebo
Number of subjects: 180
Study 19026481 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II (encapsulated resin-modified glass ionomer)
Number of subjects: 20
Study 19026481 — intervention group
Group type: EXPERIMENTAL
Intervention: Permite (amalgam)
Number of subjects: 20
Study 19026481 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek-Z-250/Single Bond (composite resin)
Number of subjects: 20
Study 19026481 — intervention group
Group type: EXPERIMENTAL
Intervention: Keta Molar (conventional glass ionomer)
Number of subjects: 20
Study 19026481 — intervention group
Group type: COMPARATOR
Intervention: Control group (composite resin)
Number of subjects: 20
Study 19026481 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer (resin-modified glass ionomer)
Number of subjects: 20
Study 16443706 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 mug twice daily
Number of subjects: 634
Study 16443706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 634
Study 15539019 — intervention group
Group type: EXPERIMENTAL
Intervention: Escin (300 mg, b.i.d.)
Number of subjects: 51
Study 15539019 — intervention group
Group type: COMPARATOR
Intervention: Loratadine (10 mg, q.d.)
Number of subjects: 51
Study 11163735 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive local muscle training (aerobic resistance training, 1 hour, three times per week for 8 weeks)
Number of subjects: 24
Study 11163735 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study 9286888 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 0
Study 9286888 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 0
Study 8360932 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with 14 vitamins and 12 minerals
Number of subjects: 3318
Study 8360932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3318
Study 3532585 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-HRSZ (3-month regimen)
Number of subjects: 300
Study 3532585 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-HRSZ3/3-HSZ2 (6-month regimen with two phases)
Number of subjects: 300
Study 3532585 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-HRSZ2 (6-month regimen, twice a week)
Number of subjects: 300
Study 29872289 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based Liuzijue exercise (WG)
Number of subjects: 50
Study 29872289 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based Liuzijue exercise (LG)
Number of subjects: 50
Study 29872289 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study 27160118 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Remifentanil (remifentanil 2 µg/kg followed by propofol 2 mg/kg)
Number of subjects: 84
Study 27160118 — intervention group
Group type: COMPARATOR
Intervention: Group Propofol (propofol 2 mg/kg followed by remifentanil)
Number of subjects: 84
Study 24635387 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 345
Study 24635387 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg
Number of subjects: 345
Study 24635387 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril/Lercanidipine 20/10 mg combination
Number of subjects: 345
Study 21793638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth Guide Training Box (TTB)
Number of subjects: 71
Study 21793638 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Learning (GL)
Number of subjects: 71
Study 20668035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT) targeting normal-for-age fasting blood glucose levels
Number of subjects: 700
Study 20668035 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion only to prevent excessive hyperglycemia (Control)
Number of subjects: 700
Study 20668035 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients experiencing hypoglycemia
Number of subjects: 700
Study 18395305 — intervention group
Group type: EXPERIMENTAL
Intervention: Healive (new preservative-free inactivated hepatitis A vaccine)
Number of subjects: 400
Study 18395305 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 400
Study 15858105 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous ablation of HCC with high-intensity focused ultrasound performed 2-4 weeks after TACE
Number of subjects: 50
Study 15858105 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE) alone
Number of subjects: 50
Study 11278231 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 165
Study 11278231 — intervention group
Group type: COMPARATOR
Intervention: Abdominal myomectomy
Number of subjects: 165
Study 11278231 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy (non-randomized group)
Number of subjects: 165
Study 9641612 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) 2.0 microg/kg i.v.
Number of subjects: 6
Study 9641612 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (DEXA) 1 mg p.o. at 23.00 h on the previous night
Number of subjects: 6
Study 9641612 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (ALP) 0.02 mg/kg p.o. at -90 min
Number of subjects: 6
Study 9641612 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX)
Number of subjects: 6
Study 8124322 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0
Study 8124322 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 8124322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2572857 — intervention group
Group type: EXPERIMENTAL
Intervention: dexfenfluramine (dF), 15 mg twice daily
Number of subjects: 822
Study 2572857 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 822
Study 2572857 — intervention group
Group type: EXPERIMENTAL
Intervention: dexfenfluramine (dF)
Number of subjects: 822
Study 979068 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirolactone (400 mg, 200 mg, or 300 mg orally daily)
Number of subjects: 15
Study 979068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 979068 — intervention group
Group type: EXPERIMENTAL
Intervention: Strophanthin (0.375 to 0.625 mg intravenously)
Number of subjects: 15
Study 31070869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 927
Study 31070869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study 28625370 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (according to standard AF dosing)
Number of subjects: 4000
Study 28625370 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 81mg daily
Number of subjects: 4000
Study 24557584 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI-directed fluid management (2 mL/kg/h crystalloid fluid infusion, rapid infusion of 250 mL colloid or crystalloid if PVI>13%)
Number of subjects: 30
Study 24557584 — intervention group
Group type: COMPARATOR
Intervention: Non PVI-directed fluid management (4‐8 mL/kg/h crystalloid fluid infusion, quick fluid infusion if mean arterial BP<65 mmHg)
Number of subjects: 30
Study 24073484 — intervention group
Group type: EXPERIMENTAL
Intervention: Announced inspections
Number of subjects: 0
Study 24073484 — intervention group
Group type: COMPARATOR
Intervention: Unannounced inspections (Control)
Number of subjects: 0
Study 21736825 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon (2 × 120 g servings/week)
Number of subjects: 44
Study 21736825 — intervention group
Group type: COMPARATOR
Intervention: Salmon oil capsules (2, 4, or 6 capsules/day)
Number of subjects: 44
Study 19418208 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-release methylphenidate
Number of subjects: 35
Study 19418208 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release amphetamine salts
Number of subjects: 35
Study 19418208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 19418208 — intervention group
Group type: COMPARATOR
Intervention: Routine limited medication regimen
Number of subjects: 35
Study 16364555 — intervention group
Group type: EXPERIMENTAL
Intervention: 17.5 mg cortisol injection
Number of subjects: 31